Related Experiment Videos
Roundtable discussion: Part II--Development of a pharmacoeconomic model in hypertension
Abstract:
Antihypertensive medications are targeted by most health plans as a major cost center. However, the efficacy of these medications, their side effects, and their resulting ability to prevent serious long-term complications must be factored into the value equation. To illustrate the possible economic effects of a single antihypertensive agent's inclusion on a health plan's drug formulary, an innovative pharmacoeconomic model was developed. In this portion of the roundtable, the design, results, and caveats of this model are discussed.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Hypertension II: Pathophysiology
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacodynamic Models: Overview
Hypertension III: Clinical Manifestations and Diagnostic Studies